Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)
A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Abbotsford, British Columbia, Canada
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
-
-
-
-
-
Frankfurt, Germany
-
Heidleberg, Germany
-
Jena, Germany
-
Magdeburg, Germany
-
Ulm, Germany
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Montgomery, Alabama, United States
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
La Jolla, California, United States
-
Oceanside, California, United States
-
Orange, California, United States
-
Palo Alto, California, United States
-
Roseville, California, United States
-
-
Colorado
-
Golden, Colorado, United States
-
-
Florida
-
Clearwater, Florida, United States
-
Gainesville, Florida, United States
-
Hialeah, Florida, United States
-
Jacksonville, Florida, United States
-
North Miami Beach, Florida, United States
-
Sarasota, Florida, United States
-
Winter Park, Florida, United States
-
-
Georgia
-
Marietta, Georgia, United States
-
Savannah, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Bloomington, Indiana, United States
-
-
Kansas
-
Topeka, Kansas, United States
-
-
Kentucky
-
Bowling Green, Kentucky, United States
-
Louisville, Kentucky, United States
-
-
Louisiana
-
Metairie, Louisiana, United States
-
-
Maryland
-
Annapolis, Maryland, United States
-
-
Massachusetts
-
Newton, Massachusetts, United States
-
-
Michigan
-
Chesterfield, Michigan, United States
-
Dearborn, Michigan, United States
-
Troy, Michigan, United States
-
-
Minnesota
-
Rochester, Minnesota, United States
-
-
Mississippi
-
Ocean Springs, Mississippi, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
Mexico, Missouri, United States
-
-
New York
-
New York, New York, United States
-
Syracuse, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
Charlotte, North Carolina, United States
-
Raleigh, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Cleveland, Ohio, United States
-
Dayton, Ohio, United States
-
-
Oklahoma
-
Tulsa, Oklahoma, United States
-
-
South Carolina
-
Columbia, South Carolina, United States
-
-
Tennessee
-
Germantown, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Irving, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Vermont
-
Burlington, Vermont, United States
-
-
Virginia
-
Chesapeake, Virginia, United States
-
Richmond, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
Milwaukee, Wisconsin, United States
-
Monroe, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)
Exclusion Criteria:
- Active or draining fistula present at screening
- Lactating and/or pregnant female subjects
- A history of any health condition that could potentially interfere with the disease and/or the treatment
- A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product
- Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study
- History of drug or alcohol abuse in the prior year
- Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
|
|
Experimental: Certolizumab pegol 400 mg
|
Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36.
Two vials will be required for each dosing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38
Time Frame: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
|
Week 38
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Subjects With Continuous Remission Off Steroids at Week 38
Time Frame: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A CDAI score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A subject with continuous remission off steroids at Week 38 is a subject in remission (CDAI =< 150) from the visit when he stops taking steroids to Week 38 and is off corticosteroids until Week 38.
|
Week 38
|
|
Cumulative Percentage of Subjects With Relapse/Treatment Failure at Week 38
Time Frame: Week 38
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
Week 38
|
|
Time to Relapse/Treatment Failure During the 38-week Double-blind Treatment Period
Time Frame: During the 38-week double-blind treatment period
|
A subject with relapse/ treatment failure has a Crohn's Disease Activity Index (CDAI) > 150 and an increase in CDAI of >= 70 points versus Week 0. [The CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.]
|
During the 38-week double-blind treatment period
|
|
Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Time Frame: Over the 38-week double-blind treatment period
|
The median weekly dose of corticosteroids is calculated for each subject, and these per-subject median values are further summarized by treatment group.
The mean of the per-subject median doses in each treatment group is presented here.
|
Over the 38-week double-blind treatment period
|
|
Per-subject Cumulative Dose of Corticosteroids Over the 48-week Study Period
Time Frame: Over the 48-week study period
|
The cumulative dose of corticosteroids over the 48-week study period is calculated for each subject individually.
The mean of these values for each treatment group is presented here.
|
Over the 48-week study period
|
|
Change From the 6-week run-in Period in Per-subject Median Weekly Dose of Corticosteroids Over the 38-week Double-blind Treatment Period
Time Frame: 6-week run-in period, 38-week double-blind treatment period
|
The run in period lasted a minimum of 1 week and a maximum of 6 weeks.
During this period subjects were treated with any dose or type of systemic corticosteroids the Investigator felt was appropriate.
To be eligible for study randomization, subjects must have been in remission (CDAI ≤150 points) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.
Subjects who did not meet these criteria were not randomized and were withdrawn from the study.
|
6-week run-in period, 38-week double-blind treatment period
|
|
Crohn's Disease Activity Index (CDAI) Score at Week 38
Time Frame: Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 38
|
|
Change From Baseline in CDAI Score at Week 38
Time Frame: Week 0, Week 38
|
The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 0, Week 38
|
|
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Time Frame: Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher score indicates a better quality of life.
IBDQ remission is defined as a subject having an IBDQ total score >= 170 points.
|
Week 38
|
|
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 38
Time Frame: Week 0, Week 38
|
The total IBDQ score will be derived as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224.
A higher scores indicates a better quality of life.
IBDQ response is defined as an increase from baseline in the IBDQ total score >= 16 points.
|
Week 0, Week 38
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C87059
- 2006-003870-88 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.